- Home
- EQ vs GNS Comparison
EQ vs GNS Comparison
Compare EQ & GNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- GNS
- Stock Information
- Founded
- EQ 2017
- GNS 2002
- Country
- EQ United States
- GNS Singapore
- Employees
- EQ N/A
- GNS N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- GNS Other Consumer Services
- Sector
- EQ Health Care
- GNS Real Estate
- Exchange
- EQ Nasdaq
- GNS Nasdaq
- Market Cap
- EQ 67.9M
- GNS 72.9M
- IPO Year
- EQ 2018
- GNS 2022
- Fundamental
- Price
- EQ $1.50
- GNS $0.97
- Analyst Decision
- EQ Hold
- GNS
- Analyst Count
- EQ 2
- GNS 0
- Target Price
- EQ $1.00
- GNS N/A
- AVG Volume (30 Days)
- EQ 2.5M
- GNS 3.0M
- Earning Date
- EQ 11-12-2025
- GNS 04-30-2025
- Dividend Yield
- EQ N/A
- GNS N/A
- EPS Growth
- EQ N/A
- GNS N/A
- EPS
- EQ N/A
- GNS N/A
- Revenue
- EQ $16,553,000.00
- GNS $7,912,718.00
- Revenue This Year
- EQ N/A
- GNS $62.23
- Revenue Next Year
- EQ N/A
- GNS $69.63
- P/E Ratio
- EQ N/A
- GNS N/A
- Revenue Growth
- EQ N/A
- GNS N/A
- 52 Week Low
- EQ $0.27
- GNS $0.21
- 52 Week High
- EQ $2.35
- GNS $1.92
- Technical
- Relative Strength Index (RSI)
- EQ 48.79
- GNS 51.86
- Support Level
- EQ $1.78
- GNS $0.91
- Resistance Level
- EQ $2.02
- GNS $1.28
- Average True Range (ATR)
- EQ 0.26
- GNS 0.11
- MACD
- EQ -0.09
- GNS 0.02
- Stochastic Oscillator
- EQ 1.73
- GNS 44.67
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About GNS Genius Group Limited
Genius Group Ltd is an Edtech and education company that provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company's business consists of two reportable business segments: Education, which involves entrepreneur education, management consultancy, and business development tools; and Campus, consisting of resorts, retreats, and co-working cafes for entrepreneurs. It derives the majority of its revenue from the Education segment. Geographically, it operates in Europe/Middle East/Africa, Asia/Pacific, and North America/South America. The company derives maximum revenue from Europe/Middle East/Africa.